DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for bent bone dysplasia syndrome 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBent bone dysplasia syndrome 1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bent bone dysplasia syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 2 (FGFR2) — FGFR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6V6Q · 2.46 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER (ACP). Experimental structure, not a prediction.
What the evidence adds up to
Bent bone dysplasia syndrome 1 is not directly studied in any of the provided abstracts. The 2017 paper describes six patients from four families with biallelic pathogenic variants in PLOD2, which causes Bruck syndrome type 2, a form of autosomal recessive osteogenesis imperfecta. Two stillborn siblings had compound heterozygous PLOD2 variants (p.Asp585Val and p.Ser166*) and a kyphomelic dysplasia-like phenotype. One infant who died at four months had a bent bone phenotype resembling skeletal dysplasia Kozlowski-Reardon, with mesomelic shortening, camptodactyly, retrognathia, cleft palate, skin dimples, and fractures; he was homozygous for p.Trp561*. Two siblings with Bruck syndrome carried the homozygous missense variant p.His687Arg. A boy with moderate osteogenesis imperfecta had a possibly pathogenic homozygous variant p.Trp588Cys. All cases had multiple fractures. The paper expands the phenotypic spectrum of PLOD2-related disease but does not test any drug.
The 2016 abstract investigates suramin sodium for fibrous dysplasia, not bent bone dysplasia. Suramin sodium blocks Gsα activation. The authors constructed a bone-targeted, pH-sensitive nanoparticle delivery system using alendronate-conjugated hyperbranched poly(amine-ester). In vitro, suramin-loaded nanoparticles inhibited proliferation of fibrous dysplasia cells, as measured by MTT assay and flow cytometry. No animal or human data are reported. The 2010 review is a general radiological overview of genetic skeletal disorders and contains no drug or treatment information.
No drug has been tested in bent bone dysplasia syndrome 1 in these abstracts. The PLOD2 variants that cause the condition are described, but no therapeutic intervention is evaluated. What is missing is any clinical trial, any drug screening in patient-derived cells, any animal model work, and any funding directed specifically at this ultra-rare syndrome. Patient stratification by specific PLOD2 genotype may be necessary, but no such stratification has been attempted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Bone and Mineral Research · 2017 · 26 citations · open access
Expanding the Clinical Spectrum of Phenotypes Caused by Pathogenic Variants in <i>PLOD2</i>
Inhibition of fibrous dysplasia via blocking Gsα with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system
AbstractSuramin sodium (SS), which can directly inhibit the committed step of Gsα activation, seems to be a promising drug for treating fibrous dysplasia (FD). Therefore, how to efficiently deliver SS to the lesion site becomes an urgent problem to be solved. Here a bone-targeted and pH-sensitive drug delivery system was constructed to deliver SS for treating FD with high efficiency. The novel type of bone-targeted cationic hyperbranched poly(amine-ester) (HBPAE) was synthesized by the proton-transfer polymerization of triethanolamine and glycidyl methacrylate, followed by surface carboxyl-modification and then conjugation of an alendronate (ALE) bone-targeting moiety. The resultant Suc-HBPAE-ALE formed nanoparticles in aqueous solution, and SS could be encapsulated into the Suc-HBPAE-ALE nanoparticles via electrostatic attraction. The dynamic light scattering (DLS) and transmission electron microscopy (TEM) assays showed that the SS-loaded nanoparticles had a spherical morphology with a mean diameter of 65 nm. The strong affinity of Suc-HBPAE-ALE nanoparticles to bone was verified by the hydroxyapatite (HA) adsorbing experiment. The therapeutic potential of the SS-loaded Suc-HBPAE-ALE nanoparticles was evaluated via the methylthiazoletetrazolium (MTT) assay and flow cytometry (FCM) analysis against FD cells. The experimental results indicated that the SS-loaded Suc-HBPAE-ALE nanoparticles were a highly promising drug delivery system with high efficiency for inhibiting the proliferation of diseased FD cells.
[Genetic basis for skeletal disease. Radiological approach for genetic skeletal disorders].
AbstractGenetic skeletal disorders comprise two broad categories, including bone dysplasia and dysostosis. Bone dysplasia refers to disorders in which the entire skeleton is more or less affected, while dysostosis to disorders in which individual bones are affected singly or in combination. The former occurs as a result of impaired genes (proteins) that play a pivotal role in both organogenesis and maintenance of bone and cartilage, while the latter as a result of impaired genes (proteins) that are important only in the organogenesis. In this review, the author focuses on radiological signs and their pathogenic mechanism commonly seen in bone dysplasias. However, it is important to realize that a radiological diagnosis of bone dysplasias depends on an overall pattern of skeletal abnormalities rather than single radiological signs, alone or in combination.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
